Edition:
United States

Five Prime Therapeutics Inc (FPRX.OQ)

FPRX.OQ on NASDAQ Stock Exchange Global Select Market

47.50USD
1:08pm EDT
Change (% chg)

$0.76 (+1.63%)
Prev Close
$46.74
Open
$46.50
Day's High
$48.11
Day's Low
$46.50
Volume
95,879
Avg. Vol
128,944
52-wk High
$60.98
52-wk Low
$26.24

Latest Key Developments (Source: Significant Developments)

Five Prime Therapeutics delivered to Inhibrx written notice of termination of agreement
Monday, 28 Aug 2017 04:09pm EDT 

Aug 28 (Reuters) - Five Prime Therapeutics Inc :‍Pursuant to terms of agreement, termination of agreement will become effective on december 27, 2017 (not 'december 27, 201')​.On august 28, 2017, Fiveprime delivered to Inhibrx written notice of termination of agreement for convenience​.  Full Article

Five Prime Therapeutics Q2 loss per share $1.58
Tuesday, 8 Aug 2017 04:05pm EDT 

Aug 8 (Reuters) - Five Prime Therapeutics Inc :Five Prime announces second quarter 2017 results and provides business update.Q2 loss per share $1.58.Q2 earnings per share view $-1.21 -- Thomson Reuters I/B/E/S.Five Prime Therapeutics - ‍cash, cash equivalents and marketable securities totaled $350.7 million on June 30, 2017, compared to $421.7 million on Dec 31, 2016​.Five Prime Therapeutics Inc - ‍collaboration revenue for Q2 of 2017 decreased by $1.4 million to $7.8 million from $9.2 million in Q2 of 2016​.Five Prime Therapeutics Inc - expects full-year 2017 net cash used in operating activities to be less than $120 million​.Five Prime Therapeutics Inc - ‍estimates ending 2017 with slightly less than $300 million in cash, cash equivalents and marketable securities​.  Full Article

Five Prime Therapeutics plans to initiate a global pivotal trial of FPA144 in 2018
Monday, 17 Jul 2017 04:10pm EDT 

July 17 (Reuters) - Five Prime Therapeutics Inc :Five prime Therapeutics initiates patient dosing in phase 1 clinical safety trial evaluating FPA144 in gastric cancer in Japan in preparation for future global late-stage development.Plans to initiate a global pivotal trial of FPA144 in 2018.  Full Article

Five Prime Therapeutics says Lewis Williams to be chairman of board in 2018
Wednesday, 21 Jun 2017 04:05pm EDT 

June 21 (Reuters) - Five Prime Therapeutics Inc ::Five Prime Therapeutics announces Lewis T. "Rusty" Williams plans to transition from CEO to executive chairman of the board in 2018.Says Dr. Williams will remain in his current role until new CEO has been appointed.Five Prime Therapeutics Inc - board will conduct a comprehensive search for a candidate to fill ceo position.Five Prime - Williams has discussed with board his desire to eventually return to executive chairman role while maintaining active role in Five Prime.  Full Article

Five Prime Therapeutics Q1 loss per share $1.21
Thursday, 4 May 2017 04:05pm EDT 

May 4 (Reuters) - Five Prime Therapeutics Inc :Five Prime announces first quarter 2017 results and provides business update.Q1 loss per share $1.21.Q1 earnings per share view $-1.03 -- Thomson Reuters I/B/E/S.Five Prime Therapeutics - company estimates ending 2017 with approximately $300 million in cash, cash equivalents and marketable securities.  Full Article

Five Prime Therapeutics announces completion of enrollment for the phase 2 of the ongoing trial of Cabiralizumab
Monday, 10 Apr 2017 04:05pm EDT 

Five Prime Therapeutics Inc : Five Prime Therapeutics announces completion of enrollment for the phase 2 part of the ongoing trial of cabiralizumab for the treatment of pigmented villonodular synovitis (PVNS) . Five Prime Therapeutics Inc - Five Prime plans to seek regulatory feedback on design of a pivotal trial .Five Prime Therapeutics - plans to present initial data from phase 2 part of trial at 2017 American Society Of Clinical Oncology (ASCO) annual meeting.  Full Article

Five Prime announces fourth quarter and full year 2016 financial results
Thursday, 23 Feb 2017 04:05pm EST 

Five Prime Therapeutics Inc : Five Prime announces fourth quarter and full year 2016 financial results . Q4 loss per share $0.73 .Q4 earnings per share view $-0.57 -- Thomson Reuters I/B/E/S.  Full Article

Five Prime Therapeutics sees 2017 net cash used in operations less than $120 mln-SEC filing
Monday, 9 Jan 2017 10:26am EST 

Five Prime Therapeutics Inc : Expects net cash used in operations for fiscal year 2017 will be less than $120 mln .Five prime therapeutics - expects that cash, cash equivalents and marketable securities as of Dec 31, 2017 will be approximately $300 mln - SEC filing.  Full Article

Five Prime Therapeutics files for potential stock shelf
Thursday, 3 Nov 2016 04:58pm EDT 

Five Prime Therapeutics Inc - :Files for potential stock shelf; size not disclosed - SEC filing.  Full Article

Five Prime reports loss per share of $0.29
Thursday, 3 Nov 2016 04:05pm EDT 

Five Prime Therapeutics Inc : Says collaboration revenue for Q3 of 2016 increased by $0.8 million to $6.7 million . Q3 revenue view $7.5 million -- Thomson Reuters I/B/E/S . Five Prime announces third quarter 2016 results and provides business update . Q3 LOSS PER SHARE $0.72 .Q3 earnings per share view $-0.51 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Five Prime to feature two oral data presentations at ESMO congress

* Five Prime to feature two oral data presentations at ESMO 2017 congress Source text for Eikon: Further company coverage: